Restrictions to the use of Esmya (ulipristal acetate) for the symptoms of uterine fibroids and the requirement to check liver function

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a letter for healthcare professionals - Esmya (ulipristal acetate) for symptoms of uterine fibroids: restrictions to use and r
Source: Royal Pharmaceutical Society News - Category: Drugs & Pharmacology Source Type: news